Arcus Biosciences, Inc. logo RCUS - Arcus Biosciences, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 15
HOLD 3
SELL 0
STRONG
SELL
0
| PRICE TARGET: $31.17 DETAILS
HIGH: $47.00
LOW: $22.00
MEDIAN: $30.00
CONSENSUS: $31.17
UPSIDE: 33.03%
Metric 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016
Revenue
Revenue 247 258 117 112 383 78 15 8.4 1.4 0
Cost of Revenue 10 0 0 0 0 0 0 0 0 1.3
Gross Profit 237 258 117 112 383 78 15 8.4 1.4 (1.3)
Operating Expenses
R&D Expenses 523 448 340 288 257 159 78.5 49.6 47.2 14.2
SG&A Expenses 110 120 117 104 72 43 25.2 13.6 7.6 3.9
Other Expenses (10) 20 0 0 0 0 0 0 0 0
Operating Expenses 623 588 457 392 329 202 103.7 63.2 54.9 18.2
Operating Income
Operating Income (386) (330) (340) (280) 54 (124) (88.7) (54.9) (53.4) (18.2)
Interest Expense 8 4 2 2 0 0 0 0 0 0
Interest Income 0 52 41 16 1 1 5.2 4.9 0.8 0.2
Profitability
EBITDA (335) (269) (291) (258) 59 (120) (81.1) (51.2) (50.8) (16.9)
EBIT (345) (279) (299) (264) 55 (123) (84.7) (54.9) (53.4) (18.2)
Income Before Tax (353) (283) (301) (266) 55 (123) (84.7) (49.6) (53.1) (18.0)
Income Tax Expense 0 1 6 1 2 0 0 0 0 0
Net Income (353) (283) (307) (267) 53 (123) (84.7) (49.6) (53.1) (18.0)
Per Share Data
EPS (Basic) -3.29 -3.14 -4.15 -3.71 0.76 -2.13 -1.73 -1.43 -2.16 -0.73
EPS (Diluted) -3.29 -3.14 -4.15 -3.71 0.71 -2.13 -1.73 -1.43 -2.16 -0.73
Shares Outstanding 107.4 90.1 74 72 69.3 54.8 43.8 34.6 24.6 24.6
Metric 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016
Current Assets
Cash & Cash Equivalents 222 150 127 206 147.9 173.4 57.9 71.1 98.4 65.2
Short-Term Investments 759 828 632 803 351.4 555.2 130.3 185.5 77.3 33.7
Net Receivables 0 25 42 43 746.8 1.7 0.1 0.1 0.0 0.4
Inventory 0 0 0 0 0 0 0 0 0 0
Other Current Assets 26 13 30 14 14.7 4.5 0.3 0 0 0
Total Current Assets 1,007 1,016 831 1,066 1,261.8 735.8 192.7 258.9 176.9 99.7
Non-Current Assets
Property, Plant & Equipment 40 47 51 135 137.4 23.6 9.3 11.1 11.2 8.6
Goodwill 0 0 0 0 0 0 0 0 0 0
Intangible Assets 0 0 0 0 0 0 0 0 0 0
Long-Term Investments 0 14 107 134 185.0 6.6 0 4.4 0.7 1
Other Non-Current Assets 92 73 106 10 7.7 6.2 1.1 0.5 1.7 0.4
Total Non-Current Assets 132 134 264 279 330.1 36.5 10.4 16.0 13.6 10.0
Total Assets 1,139 1,150 1,095 1,345 1,591.9 772.3 203.1 274.9 190.5 109.7
Current Liabilities
Account Payables 0 18 17 20 10.3 15.7 4.7 3.1 3.8 3.9
Short-Term Debt 0 0 0 3 5.1 2.9 0 0 0 0
Deferred Revenue 35 85 91 97 102.0 74.6 7 6.2 5 0
Other Current Liabilities 196 14 39 48 30.3 19.9 6.4 1.6 0.8 0.7
Total Current Liabilities 231 226 184 193 166.1 121.7 22.7 16.9 12.7 5.5
Non-Current Liabilities
Long-Term Debt 99 48 0 0 0 0 0 0 0 0
Deferred Tax Liabilities 0 0 0 0 0 0 0 0 0 0
Other Non-Current Liabilities 178 157 142 23 5.3 10.2 4.5 6.1 5.3 4.7
Total Non-Current Liabilities 277 439 449 495 584.4 148.3 16.6 23.0 23.9 4.7
Total Liabilities 508 665 633 688 750.4 270.0 39.3 40.0 36.6 10.2
Stockholders' Equity
Common Stock 2,116 1,617 1,311 1,206 0.0 0.0 0.0 0.0 0.0 0.0
Retained Earnings (1,485) (1,132) (849) (542) (275.4) (328.2) (205.3) (122.8) (73.2) (20.2)
Accumulated Other Comprehensive Income 0 0 0 (7) (1.3) 0.0 0.1 (0.1) (0.0) (0.0)
Total Stockholders' Equity 631 485 462 657 841.5 502.3 163.8 234.9 153.9 99.5
Total Liabilities & Equity 1,139 1,150 1,095 1,345 1,591.9 772.3 203.1 274.9 190.5 109.7
Debt Metrics
Total Debt 99 60 11 120 122.0 18.1 0 0 0 0
Net Debt (123) (90) (116) (86) (25.9) (155.3) (57.9) (71.1) (98.4) (65.2)
Metric 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016
Operating Activities
Net Income (353) (283) (307) (267) 52.8 (122.9) (84.7) (49.6) (53.1) (18.0)
Depreciation & Amortization 10 10 8 14 3.8 4.2 3.6 3.7 2.6 1.3
Stock-Based Compensation 60 76 73 0 55 22 9.0 3.9 0.5 0.1
Change in Working Capital (194) 22 (71) 623 (375.6) 208.1 0.1 1.3 24.6 3.6
Other Non-Cash Items (5) 5 (9) 68 3.5 (0.0) (1.4) (0.2) (0.1) 0.1
Operating Cash Flow (482) (170) (306) 438 (256.2) 111.2 (73.5) (43.0) (25.1) (12.9)
Investing Activities
Capital Expenditure (2) (6) (24) (6) (26.1) (3.1) (1.9) (3.7) (5.5) (4.1)
Acquisitions 0 0 0 0 (22) 431 0 0 0 (1)
Purchases of Investments (1,076) (1,043) (788) (1,241) (718.9) (739.7) (247.8) (261.6) (96.8) (33.8)
Sales/Maturities of Investments 1,144 965 1,006 837 741.1 308.3 308.9 151.9 53.3 1
Other Investing Activities 0 0 0 (3) 22 (431) 0 (109.7) (43.6) (1)
Investing Cash Flow 66 (84) 194 (413) (3.9) (434.4) 59.2 (113.4) (49.1) (38.9)
Financing Activities
Net Debt Issuance 49 47 0 10 5 0 0 0 0 0
Stock Repurchased 0 0 0 0 (0.0) (0.1) (0.1) 0 0 0
Dividends Paid 0 0 0 0 0 0 0 0 0 0
Other Financing Activities 0 2 8 0 12.3 4.7 1.2 4.0 0.5 0.3
Financing Cash Flow 488 277 33 33 237.3 438.7 1.1 129.1 107.4 70.1
Cash Position
Net Change in Cash 72 23 (79) 58.1 (22.7) 115.5 (13.1) (27.4) 33.3 18.3
Cash at Beginning 153 130 209 147.9 173.6 58.1 71.3 98.4 65.2 46.9
Cash at End 225 153 130 206 150.9 173.6 58.1 71.1 98.4 65.2
Free Cash Flow (484) (176) (330) 432 (282.2) 108.1 (75.4) (46.7) (30.6) (17.0)
Key Metrics 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016
Income Statement
Revenue 247 258 117 112 383 78 15 8.4 1.4 0
Gross Profit 237 258 117 112 383 78 15 8.4 1.4 (1.3)
Operating Income (386) (330) (340) (280) 54 (124) (88.7) (54.9) (53.4) (18.2)
Net Income (353) (283) (307) (267) 53 (123) (84.7) (49.6) (53.1) (18.0)
EPS (Diluted) -3.29 -3.14 -4.15 -3.71 0.71 -2.13 -1.73 -1.43 -2.16 -0.73
Balance Sheet
Cash & Equivalents 222 150 127 206 147.9 173.4 57.9 71.1 98.4 65.2
Total Assets 1,139 1,150 1,095 1,345 1,591.9 772.3 203.1 274.9 190.5 109.7
Total Debt 99 60 11 120 122.0 18.1 0 0 0 0
Stockholders' Equity 631 485 462 657 841.5 502.3 163.8 234.9 153.9 99.5
Cash Flow
Operating Cash Flow (482) (170) (306) 438 (256.2) 111.2 (73.5) (43.0) (25.1) (12.9)
Capital Expenditure (2) (6) (24) (6) (26.1) (3.1) (1.9) (3.7) (5.5) (4.1)
Free Cash Flow (484) (176) (330) 432 (282.2) 108.1 (75.4) (46.7) (30.6) (17.0)